Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.

The aim was to study the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cells in adults with B-cell lymphoma. From October 2015 to October 2021, we treated five patients with B-cell lymphoma, comprising two with mantle cell lymphoma, one case of Burkitt lymphoma, one case of diffuse large B-cell lymphoma, and one case of chronic lymphocytic leukemia/small lymphocytic lymphoma. The patients were given the FC regimen 5 days before the infusion of anti-CD19 CAR T-cells.

Development of molecular intervention strategies for B-cell lymphoma.

Introduction: There are many genetic mutations involved in B-cell lymphomagenesis. These mutations contribute to the prognosis of B-cell lymphomas and can be used for and targeted for intervention.

Areas Covered: This review provides an overview of targeted gene therapies for B-cell lymphoma that were newly approved or are under clinical development.